Skip to Content
Radiation Research Program
Contact NExT
Show menu
Search this site
Last Updated: 06/23/20
Dr Ceferino Obcemea

DR. CEFERINO OBCEMEA

PROGRAM DIRECTOR

CONTACT INFORMATION

National Cancer Institute
9609 Medical Center Dr., MSC 9727
For USPS: Bethesda, MD 20892-9727
For Express and Courier: Rockville, MD 20850
Phone: 240-276-5690
Fax: 240-276- 5827
Email: ceferino.obcemea@nih.gov

Ceferino Obcemea, Ph.D., joined Radiation Research in 2017 as Program Director in Medical Physics. He oversees a portfolio of grants that includes all aspects of clinical physics in radiation oncology, novel medical devices, new treatment modalities such as ion beam therapy, on-line imaging techniques as well as the emerging fields of AI applications in radiotherapy, Big Data analytics and machine learning. He also serves as the NCI medical physics liaison to the various clinical trial groups comprising the National Clinical Trials Network (NCTN).

Prior to coming to NCI, Dr. Obcemea had many years of experience as chief physicist at Memorial Sloan Kettering Cancer Center (Westchester campus NY), Beth Israel Medical Center in New York City and Georgetown University (Frederick campus). He received his clinical training at the Joint Center for Radiation Therapy, Harvard Medical School in Boston and is board-certified by the American Board of Radiology.

Dr. Obcemea completed his Ph.D. in Physics from Uppsala University, Sweden in the fields of many-body scattering theory and non-equilibrium quantum statistical mechanics. He received various research fellowships from the Svenska Institutet (Stockholm), Niels Bohr Institute (Copenhagen), International Center for Theoretical Physics, ICTP (Trieste) and the Quantum Theory Project (QTP) at the University of Florida, Gainesville among others.

His current interests include machine designs for more affordable, compact, more robust accelerators, harmonization of clinical trial databases for discovery extraction and machine learning, radiomics for radiation oncology, new treatment regimens with particle beams, and radioimmunotherapy.

Molecular Radiation Therapeutics Branch